Jane A O'Halloran1, John Sahrmann1, Anne M Butler1,2, Margaret A Olsen1,2, William G Powderly1. 1. Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO; and. 2. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO.
Abstract
BACKGROUND: Several antiretroviral therapy (ART) classes have been associated with increased myocardial infarction (MI) risk. Cardiovascular disease in people living with HIV (PLWH) on integrase strand transfer inhibitors (INSTI) has not been examined. Here we aim to examine this. SETTING: Retrospective cohort design study. METHODS: We used the IBMMarketScan databases for U.S. commercially insured and Medicaid covered adults to identify PLWH newly initiated on ART between January 1, 2008 and December 30, 2015. Major adverse cardiac event (MACE), a composite of acute MI, ischemic stroke, coronary artery bypass grafting, and percutaneous coronary intervention was the primary outcome. We used calendar time-specific probability-weighted Cox proportional hazards models to estimate hazard ratios and 95% confidence intervals for the association between INSTI use and MACE. We used propensity score weighting methods to account for potential confounding. RESULTS: Twenty thousand two hundred forty-two new ART initiators were identified. 5069 (25%) PLWH initiated INSTI-based regimens. 203 MACE events occurred; acute MI 16 (0.32%) vs 66 (0.43%), stroke 24 (0.47%) vs 54 (0.36), coronary artery bypass grafting 2 (0.04%) vs 9 (0.06%), percutaneous coronary intervention 7 (0.14%) vs 25 (0.16%) of INSTI users vs non-users. INSTI-based ART was associated with significantly lower risk of MACE events (hazard ratios 0.79; 95% confidence intervals: 0.64 to 0.96) compared with non-INSTI-based regimens. CONCLUSION: In this cohort, INSTI-based regimens were associated with a 21% decreased risk of incident cardiovascular disease. These finding require validation in other cohorts and with longer follow-up.
BACKGROUND: Several antiretroviral therapy (ART) classes have been associated with increased myocardial infarction (MI) risk. Cardiovascular disease in people living with HIV (PLWH) on integrase strand transfer inhibitors (INSTI) has not been examined. Here we aim to examine this. SETTING: Retrospective cohort design study. METHODS: We used the IBMMarketScan databases for U.S. commercially insured and Medicaid covered adults to identify PLWH newly initiated on ART between January 1, 2008 and December 30, 2015. Major adverse cardiac event (MACE), a composite of acute MI, ischemic stroke, coronary artery bypass grafting, and percutaneous coronary intervention was the primary outcome. We used calendar time-specific probability-weighted Cox proportional hazards models to estimate hazard ratios and 95% confidence intervals for the association between INSTI use and MACE. We used propensity score weighting methods to account for potential confounding. RESULTS: Twenty thousand two hundred forty-two new ART initiators were identified. 5069 (25%) PLWH initiated INSTI-based regimens. 203 MACE events occurred; acute MI 16 (0.32%) vs 66 (0.43%), stroke 24 (0.47%) vs 54 (0.36), coronary artery bypass grafting 2 (0.04%) vs 9 (0.06%), percutaneous coronary intervention 7 (0.14%) vs 25 (0.16%) of INSTI users vs non-users. INSTI-based ART was associated with significantly lower risk of MACE events (hazard ratios 0.79; 95% confidence intervals: 0.64 to 0.96) compared with non-INSTI-based regimens. CONCLUSION: In this cohort, INSTI-based regimens were associated with a 21% decreased risk of incident cardiovascular disease. These finding require validation in other cohorts and with longer follow-up.
Authors: K Petoumenos; P Reiss; L Ryom; M Rickenbach; C A Sabin; W El-Sadr; A d'Arminio Monforte; A N Phillips; S De Wit; O Kirk; F Dabis; C Pradier; J D Lundgren; M G Law Journal: HIV Med Date: 2014-05-19 Impact factor: 3.180
Authors: Paul E Sax; Edwin DeJesus; Anthony Mills; Andrew Zolopa; Calvin Cohen; David Wohl; Joel E Gallant; Hui C Liu; Lijie Zhong; Kitty Yale; Kirsten White; Brian P Kearney; Javier Szwarcberg; Erin Quirk; Andrew K Cheng Journal: Lancet Date: 2012-06-30 Impact factor: 79.321
Authors: Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 9.079
Authors: Jane A O'Halloran; Eimear Dunne; Willard Tinago; Stephanie Denieffe; Dermot Kenny; Patrick W G Mallon Journal: AIDS Date: 2018-04-24 Impact factor: 4.177
Authors: Christina DeFilippo Mack; Robert J Glynn; M Alan Brookhart; William R Carpenter; Anne Marie Meyer; Robert S Sandler; Til Stürmer Journal: Pharmacoepidemiol Drug Saf Date: 2013-01-07 Impact factor: 2.890
Authors: Susan M Graham; Robin M Nance; Junmei Chen; Jennie Le; Dominic W Chung; Mark M Wurfel; David L Tirschwell; Joseph R Zunt; Christina M Marra; Emily L Ho; Andrew Huffer; Felicia C Chow; Jeffrey N Martin; Alice S Ryan; Heidi M Crane; José A López; W Conrad Liles Journal: Open Forum Infect Dis Date: 2021-10-21 Impact factor: 4.423
Authors: Pablo Villoslada-Blanco; Patricia Pérez-Matute; María Íñiguez; Emma Recio-Fernández; Pilar Blanco-Navarrete; Luis Metola; Valvanera Ibarra; Jorge Alba; María de Toro; José A Oteo Journal: Infect Dis Ther Date: 2022-05-26